Two cases of olanzapine-induced reversible neutropenia

被引:35
作者
Steinwachs, A
Grohmann, R
Pedrosa, F
Rüther, E
Schwerdtner, I
机构
[1] Univ Munich, Psychiat Klin, Dept Psychiat, D-80336 Munich, Germany
[2] Hosp Psychiat, Weinsberg, Germany
[3] Univ Gottingen, Dept Psychiat, D-3400 Gottingen, Germany
[4] Lilly Deutschland, Bad Homburg, Germany
关键词
D O I
10.1055/s-2007-979222
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Olanzapine is a tricyclic neuroleptic agent that due to structural similarities was expected to be a safe alternative to clozapine, which has a 0.5 -2% risk of agranulocytosis. So far, only rare cases of leukocytopenia and thrombocytopenia have become known. In the association,,Drug Safety in Psychiatry", which is made up of 25 German psychiatric hospitals, two cases of olanzapine-induced neutropenia occurred in patients with chronic schizophrenia. The adverse drug reaction was noticed 17 days after the first intake of olanzapine in case 1 and more than 5 months after the first intake in case 2. in the second case, a reexposure to olanzapine caused the neutrophil cells to decrease again. There were no clinical signs of an infection, and the blood cell counts increased immediately to normal ranges after discontinuation of olanzapine. No special treatment was necessary.
引用
收藏
页码:154 / 156
页数:3
相关论文
共 18 条
  • [1] CLOZAPINE-INDUCED AGRANULOCYTOSIS - INCIDENCE AND RISK-FACTORS IN THE UNITED-STATES
    ALVIR, JMJ
    LIEBERMAN, JA
    SAFFERMAN, AZ
    SCHWIMMER, JL
    SCHAAF, JA
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1993, 329 (03) : 162 - 167
  • [2] CLOZAPINE-INDUCED AGRANULOCYTOSIS - SITUATION REPORT UP TO AUGUST 1976
    ANDERMAN, B
    GRIFFITH, RW
    [J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1977, 11 (03) : 199 - 201
  • [3] Beasley CM, 1997, J CLIN PSYCHIAT, V58, P13
  • [4] Olanzapine versus placebo: Results of a double-blind, fixed-dose olanzapine trial
    Beasley, CM
    Sanger, T
    Satterlee, W
    Tollefson, G
    Tran, P
    Hamilton, S
    Green, A
    Dott, S
    Pfister, G
    Roxas, L
    Small, J
    Thomas, M
    Ames, D
    Schooler, N
    Baker, R
    Levine, R
    Fabre, L
    Friedel, R
    Safferman, A
    Lieberman, J
    Stahl, S
    [J]. PSYCHOPHARMACOLOGY, 1996, 124 (1-2) : 159 - 167
  • [5] Olanzapine versus haloperidol: Acute phase results of the international double-blind olanzapine trial
    Beasley, CM
    Hamilton, SH
    Crawford, AM
    Dellva, MA
    Tollefson, GD
    Tran, PV
    Blin, O
    Beuzen, JN
    [J]. EUROPEAN NEUROPSYCHOPHARMACOLOGY, 1997, 7 (02) : 125 - 137
  • [6] Olanzapine versus placebo and haloperidol - Acute phase results of the North American double-blind olanzapine trial
    Beasley, CM
    Tollefson, G
    Tran, P
    Satterlee, W
    Sanger, T
    Hamilton, S
    Fabre, L
    Small, J
    Ereshefsky, L
    True, J
    Nemeroff, C
    Risch, SC
    Perry, PJ
    Potkin, SG
    Borison, RL
    James, S
    Meltzer, HY
    Iqbal, N
    Fann, WE
    Gewirtz, GR
    Landbloom, R
    RoyByrne, PP
    Tuason, VB
    Carman, JS
    Stokes, PE
    Williams, R
    Ancill, RJ
    MacEwan, GW
    Gujavarty, KS
    Jones, B
    Lohr, JB
    [J]. NEUROPSYCHOPHARMACOLOGY, 1996, 14 (02) : 111 - 123
  • [7] Casey DE, 1997, J CLIN PSYCHIAT, V58, P55
  • [8] Olanzapine - A review of its pharmacological properties and therapeutic efficacy in the management of schizophrenia and related psychoses
    Fulton, B
    Goa, KL
    [J]. DRUGS, 1997, 53 (02) : 281 - 298
  • [9] Assessment of adverse drug reactions in psychiatric inpatients with the AMSP drug safety program:: Methods and first results for tricyclic antidepressants and SSRI
    Grohmann, R
    Rüther, E
    Engel, RR
    Hippius, H
    [J]. PHARMACOPSYCHIATRY, 1999, 32 (01) : 21 - 28
  • [10] GROHMANN R, 1988, ARCH GEN PSYCHIAT, V45, P789